PEDOMAN PENANGANAN FLU BURUNG DARI WHOIN NONPANDEMIC SITUATION recommendation for treatment of patients with confirmed or strongly suspected infection with Avian Flu A(H5N1) are as follows:

Patients should receive Oseltamivir treatment as soon as possible(strong recommendation)

Clinicians might administer Zanamivir(weak recommendation) If Neuraminidase inhibitors are available,clinicians should not administer

Amantadin alone as a first line treatment(strong recommendation) If Neuraminidase inhibitors are not available and especially the virus is known or

likely to be susceptible,clinicians might administer Amantadin as a first line treatment(weak recommendation)

If Neuraminidase inhibitors are available,clinicians should not administer Rimantadine alone as a first line treatment(strong recommendation)

If Neuraminidase inhibitors are not available and especially if the virus is known or likely to be susceptible,clinicians might administer Rimantadine as a first line treatment(weak recommendation)

If Neuraminidase inhibitors are available and especially if the virus is known or likely to be susceptible,clinicians might administer a combination of Neuraminidase inhibitors and M2 inhibitors(weak recommendation).This should only be done in the contex of prospective data collection

High risk exposure groups should receive Oseltamivir as chemoprophylaxis continuing for 7 to 10 days after the last known exposure(strong recommendation)

In moderate risk exposure groups,Oseltamivir may be administered as chemoprophylaxis,continuing for 7 to 10 days after the last known exposure(weak recommendation)

Low risk exposure groups should probably nor receive Oseltamivir for chemoprophylaxis(weak recommendation)